摘要
目的:研究Fas蛋白(CD95/Apol21,Fas)、Fas配体(Fasligand,FasL)在乳腺癌组织中的表达,并探讨其与淋巴结转移的关系。方法:采用免疫组化LSAB法检测50例乳腺癌组织Fas和FasL的表达。结果:Fas及FasL在乳腺癌组织中的阳性表达率分别为38和82。乳腺癌组织FasL的阳性表达率明显高于正常组织(P<0.05),Fas明显低于正常组织(P<0.05)。Fas的表达与淋巴结转移有关(P<0.05)。结论:Fas及FasL的表达与乳腺癌的临床特征和预后有关。
Objective： To study the expression of Fas and FasL in human breast carcinoma, explore the relationship between the expression levels and lymphatic metastasis. Methods： Immunohistochemistry LSAB method was used to detect the expression of Fas and FasL in 50 breast carcinoma tissues and 12 normal breast tissues. Results： The expression of Fas and FasL had significant difference between breast carcinoma tissues and normal breast tissues （ P 〈 0. 05 ）. The positive expression rates of Fas and FasL were 38% and 82%, respectively. The positive expression rate of FasL in breast carcinoma was significantly higher than that in normal tissues （ P 〈 0. 05 ）, while the positive expression rate of Fas was significantly lower than that in normal tissues （ P 〈 0. 05）. Lymphatic metastasis was effected by the expression of Fas （ P 〈 0. 05 ） . Conclusion： The abnormal expression of Fas and FasL are related to clinical features and prognosis of human breast carcinoma.
出处
《中国妇幼保健》
CAS
北大核心
2008年第35期4973-4974,共2页
Maternal and Child Health Care of China
基金
江苏省教育厅资助项目
编号:20060086
